Navigation Links
Minimally Invasive Treatment Offers Hope for Liver Cancer Patients
Date:3/13/2008

In 2007, over 85% of liver cancer treatments performed in interventional

radiology suites used transcatheter chemoembolization, according to

Millennium Research Group

WALTHAM, Mass., March 13 /PRNewswire/ -- Data from Millennium Research Group's (MRG's) US Interventional Radiology (IR) Marketrack(TM) indicates that in 2007, over 85% of liver cancer treatments performed in IR suites used transcatheter chemoembolization, a procedure that delivers chemotherapy agents directly to a tumor through minimally invasive means.

Microsphere particles, including Boston Scientific's Contour SE, Biosphere Medical's Embosphere, and others, were used in 40% of these treatments. Overall, chemoembolization particles generated nearly 20% of total microsphere revenue. As such, chemoembolization procedures are a key segment in the overall embolic particle market, which, in addition to standard microspheres, includes drug-infused microspheres, selective internal radiation therapy (SIRT) spheres, and polyvinyl alcohol (PVA) particles. MRG's US IR Marketrack(TM) service monitors the adoption of embolic particles for liver cancer, uterine fibroids, aneurysms, hemorrhages, and vascular anomalies.

"In chemoembolization, chemotherapy agents are mixed with embolic particles and are delivered through a catheter directly to the tumor, thereby localizing the chemo treatment" says Phil Scrutton, Analyst at MRG. "The particles also embolize the surrounding arteries, blocking blood flow to the cancerous tissue. This slows diffusion of the chemotherapy agents away from the tumor, which increases its effectiveness in targeting the liver tumor, while the embolization also deprives the tumor of oxygen and nutrients."

Liver cancer has historically had a poor prognosis, but the use of embolic particles in conjunction with drugs in chemoembolization, while not a cure, is leading to longer life expectancies for cancer sufferers. These positive clinical outcomes, the availability of improved embolization technologies, and an increasing rate of patient referrals for this treatment are all contributing to embolic particle market growth.

Millennium Research Group will be attending the Society of Interventional Radiology annual meeting in Washington, DC from March 16-19. Come to booth #304 to discover how we can help you meet your needs.

About Interventional Radiology Marketrack(TM)

IR Marketrack(TM) gathers quarterly data from interventional radiology labs throughout the US, including data on PV embolizations, varicose vein treatments, and vascular access procedures. Marketrack(TM) subscribers receive thousands of data points, including usage (units, average selling price, and revenue), procedure, competitor, and device brand information.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Microfabrica Introduces Set of Miniature Building Blocks for Minimally-Invasive Medical Devices
2. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
3. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
4. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
5. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
6. Masimo Announces Continuous Noninvasive Total Hemoglobin
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) announced that, ... the size of the offering by 75% and purchase 3,684,212 ... to purchase 1,842,106 shares of common stock of the Company ... stock (the "Exercise Price"), at a price to the public ... The warrants have a term of four (4) years, exercisable ...
(Date:1/24/2017)... ... January 24, 2017 , ... Men who ... leptin levels had a positive association with increased prostate growth or benign prostatic ... International Neurourology Journal involved 571 Korean men who underwent urological examinations, including ...
(Date:1/24/2017)... Geneva, Switerland (PRWEB) , ... January 24, 2017 ... ... the first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of ... panels, which are available in a range of concentrations from six different malaria ...
(Date:1/24/2017)... 24, 2017 /PRNewswire/ - ProMetic Life Sciences Inc. (TSX: PLI) ... its orally active lead drug candidate, PBI-4050, has been ... UK Medicines and Healthcare Products Regulatory Agency ("MHRA") for ... A PIM designation is an early indication that a ... Access to Medicines Scheme ("EAMS"), intended for the treatment, ...
Breaking Biology Technology:
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider ... introduction of Onitor Track, an innovative biometric data-driven program ... showcasing this month at the 2017 Consumer Electronics Show ... In the U.S., the World Health Organization ... than two-thirds of adults who are overweight or obese. ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/16/2016)... global wearable medical device market, in terms of value, is projected ... in 2016, at a CAGR of 18.0% during the forecast period. ... Growth in ... launch of a growing number of smartphone-based healthcare apps compatible with ... increasing focus on physical fitness. Furthermore, growing trend ...
Breaking Biology News(10 mins):